Loading...
•
Jun 30, 2025
Castle Biosciences Q2 2025 Earnings Report
Estimated Revenue:$71.5M
+1.1% YoY
Estimated EPS:-$0.49
78.1% YoY
Key Takeaways
Castle Biosciences delivered a strong second quarter in 2025, achieving $86 million in revenue. The company saw solid year-over-year test volume growth in its core revenue drivers, DecisionDx-Melanoma and TissueCypher, which exceeded expectations. This performance led to an upward revision of the full-year 2025 revenue guidance.
Q2 2025 revenue reached $86 million, demonstrating strong top-line performance.
Total test reports for core revenue drivers (DecisionDx-Melanoma, TissueCypher) increased by 33% over Q2 2024.
Full-year 2025 revenue guidance was raised to $310-320 million from the previous $287-297 million.
The company completed the Previse tuck-in acquisition and announced a collaboration with SciBase, aligning with its capital allocation and M&A strategy.
Forward Guidance
Castle Biosciences has raised its full-year 2025 revenue guidance, reflecting confidence in continued strong performance.
Positive Outlook
- Anticipated total revenue for 2025 is now between $310-320 million, an increase from previous guidance.
- Strong performance in Q2 2025, particularly in core revenue drivers, supports the raised outlook.
- Strategic acquisitions and collaborations are expected to support mid- to long-term value creation.
- Continued focus on execution across the current test portfolio is expected to drive near-term success.
- The company's ability to invest in the future while advancing core franchises indicates strong growth initiatives.
Loading...
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...